How the study of children with rheumatic diseases identified interferon-α and interleukin-1 as novel therapeutic targets

Virginia Pascual, Florence Allantaz, Pinakeen Patel, A. Karolina Palucka, Damien J. Chaussabel, Jacques Banchereau

Research output: Contribution to journalReview article

57 Citations (Scopus)

Abstract

Our studies in children with rheumatic diseases have led to the identification of two of the oldest cytokines, type I interferon (IFN) and interleukin 1 (IL-1), as important pathogenic players in systemic lupus erythematosus (SLE) and systemic onset juvenile arthritis (SoJIA), respectively. These findings were obtained by studying the transcriptional profiles of patient blood cells and by assessing the biological and transcriptional effect(s) of active patient sera on healthy blood cells. We also identified a signature that can be used to promptly diagnose SoJIA from other febrile conditions. Finally, our pilot clinical trials using IL-1 blockers have shown remarkable clinical benefits in SoJIA patients refractory to other medications.

Original languageEnglish
Pages (from-to)39-59
Number of pages21
JournalImmunological Reviews
Volume223
Issue number1
DOIs
Publication statusPublished - Jun 2008
Externally publishedYes

Fingerprint

Juvenile Arthritis
Rheumatic Diseases
Interleukin-1
Interferons
Blood Cells
Interferon Type I
Systemic Lupus Erythematosus
Fever
Therapeutics
Clinical Trials
Cytokines
Serum

Keywords

  • Interferon (IFN)
  • Interleukin 1 (IL-1)
  • Microarray
  • Systemic lupus erythematosus (SLE)
  • Systemic onset juvenile idiopathic arthritis (SOJIA)

ASJC Scopus subject areas

  • Immunology

Cite this

How the study of children with rheumatic diseases identified interferon-α and interleukin-1 as novel therapeutic targets. / Pascual, Virginia; Allantaz, Florence; Patel, Pinakeen; Palucka, A. Karolina; Chaussabel, Damien J.; Banchereau, Jacques.

In: Immunological Reviews, Vol. 223, No. 1, 06.2008, p. 39-59.

Research output: Contribution to journalReview article

Pascual, Virginia ; Allantaz, Florence ; Patel, Pinakeen ; Palucka, A. Karolina ; Chaussabel, Damien J. ; Banchereau, Jacques. / How the study of children with rheumatic diseases identified interferon-α and interleukin-1 as novel therapeutic targets. In: Immunological Reviews. 2008 ; Vol. 223, No. 1. pp. 39-59.
@article{cf23516b681a4a01888f60a92fb4d117,
title = "How the study of children with rheumatic diseases identified interferon-α and interleukin-1 as novel therapeutic targets",
abstract = "Our studies in children with rheumatic diseases have led to the identification of two of the oldest cytokines, type I interferon (IFN) and interleukin 1 (IL-1), as important pathogenic players in systemic lupus erythematosus (SLE) and systemic onset juvenile arthritis (SoJIA), respectively. These findings were obtained by studying the transcriptional profiles of patient blood cells and by assessing the biological and transcriptional effect(s) of active patient sera on healthy blood cells. We also identified a signature that can be used to promptly diagnose SoJIA from other febrile conditions. Finally, our pilot clinical trials using IL-1 blockers have shown remarkable clinical benefits in SoJIA patients refractory to other medications.",
keywords = "Interferon (IFN), Interleukin 1 (IL-1), Microarray, Systemic lupus erythematosus (SLE), Systemic onset juvenile idiopathic arthritis (SOJIA)",
author = "Virginia Pascual and Florence Allantaz and Pinakeen Patel and Palucka, {A. Karolina} and Chaussabel, {Damien J.} and Jacques Banchereau",
year = "2008",
month = "6",
doi = "10.1111/j.1600-065X.2008.00643.x",
language = "English",
volume = "223",
pages = "39--59",
journal = "Immunological Reviews",
issn = "0105-2896",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - How the study of children with rheumatic diseases identified interferon-α and interleukin-1 as novel therapeutic targets

AU - Pascual, Virginia

AU - Allantaz, Florence

AU - Patel, Pinakeen

AU - Palucka, A. Karolina

AU - Chaussabel, Damien J.

AU - Banchereau, Jacques

PY - 2008/6

Y1 - 2008/6

N2 - Our studies in children with rheumatic diseases have led to the identification of two of the oldest cytokines, type I interferon (IFN) and interleukin 1 (IL-1), as important pathogenic players in systemic lupus erythematosus (SLE) and systemic onset juvenile arthritis (SoJIA), respectively. These findings were obtained by studying the transcriptional profiles of patient blood cells and by assessing the biological and transcriptional effect(s) of active patient sera on healthy blood cells. We also identified a signature that can be used to promptly diagnose SoJIA from other febrile conditions. Finally, our pilot clinical trials using IL-1 blockers have shown remarkable clinical benefits in SoJIA patients refractory to other medications.

AB - Our studies in children with rheumatic diseases have led to the identification of two of the oldest cytokines, type I interferon (IFN) and interleukin 1 (IL-1), as important pathogenic players in systemic lupus erythematosus (SLE) and systemic onset juvenile arthritis (SoJIA), respectively. These findings were obtained by studying the transcriptional profiles of patient blood cells and by assessing the biological and transcriptional effect(s) of active patient sera on healthy blood cells. We also identified a signature that can be used to promptly diagnose SoJIA from other febrile conditions. Finally, our pilot clinical trials using IL-1 blockers have shown remarkable clinical benefits in SoJIA patients refractory to other medications.

KW - Interferon (IFN)

KW - Interleukin 1 (IL-1)

KW - Microarray

KW - Systemic lupus erythematosus (SLE)

KW - Systemic onset juvenile idiopathic arthritis (SOJIA)

UR - http://www.scopus.com/inward/record.url?scp=47249152715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249152715&partnerID=8YFLogxK

U2 - 10.1111/j.1600-065X.2008.00643.x

DO - 10.1111/j.1600-065X.2008.00643.x

M3 - Review article

VL - 223

SP - 39

EP - 59

JO - Immunological Reviews

JF - Immunological Reviews

SN - 0105-2896

IS - 1

ER -